title: Effectiveness of mycophenolate mofetil in C3 glomerulonephritis.
abstract: C3 glomerulonephritis is a clinicopathologic entity defined by the presence of isolated or dominant deposits of C3 on immunofluorescence. To explore the effect of immunosuppression on C3 glomerulonephritis, we studied a series of 60 patients in whom a complete registry of treatments was available over a median follow-up of 47 months. Twenty patients had not received immunosuppressive treatments. In the remaining 40 patients, 22 had been treated with corticosteroids plus mycophenolate mofetil while 18 were treated with other immunosuppressive regimens (corticosteroids alone or corticosteroids plus cyclophosphamide). The number of patients developing end-stage renal disease was significantly lower among treated compared with untreated patients (3 vs. 7 patients, respectively). No patient in the corticosteroids plus mycophenolate mofetil group doubled serum creatinine nor developed end-stage renal disease, as compared with 7 (significant) and 3 (not significant), respectively, in patients treated with other immunosuppressive regimens. Renal survival (100, 80, and 72% at 5 years) and the number of patients achieving clinical remission (86, 50, and 25%) were significantly higher in patients treated with corticosteroids plus mycophenolate mofetil as compared with patients treated with other immunosuppressive regimens and untreated patients, respectively. Thus, immunosuppressive treatments, particularly corticosteroids plus mycophenolate mofetil, can be beneficial in C3 glomerulonephritis.
authors.affiliation: Hospital 12 Octubre, Madrid, Spain.
authors.forename: Cristina
authors.initials: C
authors.lastname: Rabasco
authors.affiliation: Hospital 12 Octubre, Madrid, Spain.
authors.forename: Teresa
authors.initials: T
authors.lastname: Cavero
authors.affiliation: Hospital La Fe, Valencia, Spain.
authors.forename: Elena
authors.initials: E
authors.lastname: Román
authors.affiliation: Hospital Fundacion Jimenez Diaz, Madrid, Spain.
authors.forename: Jorge
authors.initials: J
authors.lastname: Rojas-Rivera
authors.affiliation: Hospital La Paz, Madrid, Spain.
authors.forename: Teresa
authors.initials: T
authors.lastname: Olea
authors.affiliation: Hospital Reina Sofía, Córdoba, Spain.
authors.forename: Mario
authors.initials: M
authors.lastname: Espinosa
authors.affiliation: Hospital Virgen del Rocio, Sevilla, Spain.
authors.forename: Virginia
authors.initials: V
authors.lastname: Cabello
authors.affiliation: Hospital Fundacion Alcorcon, Madrid, Spain.
authors.forename: Gema
authors.initials: G
authors.lastname: Fernández-Juarez
authors.affiliation: Hospital Dr Negrín, Gran Canaria, Spain.
authors.forename: Fayna
authors.initials: F
authors.lastname: González
authors.affiliation: Hospital Pesset, Valencia, Spain.
authors.forename: Ana
authors.initials: A
authors.lastname: Ávila
authors.affiliation: Hospital San Agustín, Aviles, Spain.
authors.forename: José María
authors.initials: JM
authors.lastname: Baltar
authors.affiliation: Hospital Fundacion Puigvert, Barcelona, Spain.
authors.forename: Montserrat
authors.initials: M
authors.lastname: Díaz
authors.affiliation: Hospital Fundacion Jimenez Diaz, Madrid, Spain.
authors.forename: Raquel
authors.initials: R
authors.lastname: Alegre
authors.affiliation: University Hospital Ramón y Cajal, Madrid, Spain.
authors.forename: Sandra
authors.initials: S
authors.lastname: Elías
authors.affiliation: Pediatric Nephrology, Hospital Reina Sofía, Cordoba, Spain.
authors.forename: Monserrat
authors.initials: M
authors.lastname: Antón
authors.affiliation: Hospital Carlos Haya, Málaga, Spain.
authors.forename: Miguel Angel
authors.initials: MA
authors.lastname: Frutos
authors.affiliation: Hospital Central de Asturias, Oviedo, Spain.
authors.forename: Alfonso
authors.initials: A
authors.lastname: Pobes
authors.affiliation: Hospital Clinic, Barcelona, Spain.
authors.forename: Miguel
authors.initials: M
authors.lastname: Blasco
authors.affiliation: Fundación Hospital Calahorra, Logroño, Spain.
authors.forename: Francisco
authors.initials: F
authors.lastname: Martín
authors.affiliation: Hospital La Princesa, Madrid, Spain.
authors.forename: Carmen
authors.initials: C
authors.lastname: Bernis
authors.affiliation: Hospital Nuestra Señora de la Candelaria, Santa Cruz de Tenerife, Spain.
authors.forename: Manuel
authors.initials: M
authors.lastname: Macías
authors.affiliation: Hospital Infanta Cristina, Badajoz, Spain.
authors.forename: Sergio
authors.initials: S
authors.lastname: Barroso
authors.affiliation: Hospital Guadalajara, Guadalajara, Spain.
authors.forename: Alberto
authors.initials: A
authors.lastname: de Lorenzo
authors.affiliation: Hospital Vall d'Hebrón, Barcelona, Spain.
authors.forename: Gema
authors.initials: G
authors.lastname: Ariceta
authors.affiliation: Hospital Virgen del Rocio, Sevilla, Spain.
authors.forename: Manuel
authors.initials: M
authors.lastname: López-Mendoza
authors.affiliation: Hospital La Paz, Madrid, Spain.
authors.forename: Begoña
authors.initials: B
authors.lastname: Rivas
authors.affiliation: Hospital Fundacion Alcorcon, Madrid, Spain.
authors.forename: Katia
authors.initials: K
authors.lastname: López-Revuelta
authors.affiliation: Hospital Clinic, Barcelona, Spain.
authors.forename: José María
authors.initials: JM
authors.lastname: Campistol
authors.affiliation: Hospital La Fe, Valencia, Spain.
authors.forename: Santiago
authors.initials: S
authors.lastname: Mendizábal
authors.affiliation: Centro de Investigaciones Biológicas, Consejo Superior de Investigaciones Científicas, Madrid, Spain.
authors.forename: Santiago Rodríguez
authors.initials: SR
authors.lastname: de Córdoba
authors.affiliation: Hospital 12 Octubre, Madrid, Spain.|Department of Medicine, Universidad Complutense, Madrid, Spain.
authors.forename: Manuel
authors.initials: M
authors.lastname: Praga
mesh_terms: D000293:Adolescent; D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000328:Adult; D000368:Aged; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D003176:Complement C3; D003404:Creatinine / Q000097:blood; D003520:Cyclophosphamide / Q000627:therapeutic use; D018450:Disease Progression; D004359:Drug Therapy, Combination; D005260:Female; D005500:Follow-Up Studies; D005921:Glomerulonephritis / Q000150:complications / Q000188:drug therapy* / Q000276:immunology; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D007676:Kidney Failure, Chronic / Q000209:etiology; D008297:Male; D008875:Middle Aged; D009173:Mycophenolic Acid / Q000031:analogs & derivatives* / Q000627:therapeutic use; D012189:Retrospective Studies; D015996:Survival Rate; D055815:Young Adult
chemical_list: D000305:Adrenal Cortex Hormones; D000893:Anti-Inflammatory Agents; D003176:Complement C3; D007166:Immunosuppressive Agents; D003520:Cyclophosphamide; D003404:Creatinine; D009173:Mycophenolic Acid